Top Biotech Companies (3,518)

Strong Revenue Growth: Growth accelerated from mid‑single‑digit in 2024–2025 to double‑digit in Q1–Q2 2026, with sales up around 10% reported and even higher on a daily organic constant‑currency basis. The company also raised full‑year 2026 sales guidance, signaling continued momentum.

Profitability: After softer 2025 results, operating earnings, EPS, and margins rose sharply in Q1–Q2 2026 (e.g., operating earnings up about 18–19% and diluted EPS up roughly 18–21% year over year). Management lifted adjusted EPS guidance alongside margin expansion.

Strong Market Position & Advantage: The company is described as a leading broad‑line MRO distributor with significant scale and a dual model (High‑Touch Solutions and Endless Assortment) supporting growth across segments. Industry coverage and company materials place it at or near the top of North American MRO distribution.

Strong Revenue Growth: Revenue increased 19% in 2025 and accelerated in 2026 with 22% year-over-year growth in Q1 and 27% in Q2, while first-half 2026 revenue rose 25% year over year. Management raised full-year 2026 guidance to $94–96M, implying roughly 22–24% growth.

Customer Loyalty & Retention: Net Dollar Retention reached 117% in Q1 2026, indicating expanding spend from existing accounts after churn. Core genomics customers rose to 537 as of March 31, 2026, with record new customer additions in 2025.

Market Expansion: Geographic momentum is evident with Q1 2026 analysis volume up 28% in the U.S. and 31% in APAC, and EMEA revenue up 30%. Platform usage set records (e.g., 108,000 analyses in Q1 and 115,000 in Q2), with liquid biopsy volumes growing sharply.

Investor Backing & Capital Strength: Recent financing includes a $50 million Series D anchored by Boehringer Ingelheim, following a Series C in 2025 and prior debt financing, indicating sustained access to strategic capital. The transfer of CT-155 commercialization responsibility alongside dedicated commercial funding further underscores capital support aligned with near-term growth plans.

Strategic Partnerships: Collaborations with major pharmaceutical companies such as Otsuka and Boehringer Ingelheim, alongside agreements with Indivior and Ultrahuman, reflect deepening partner engagement in development and commercialization. These alliances have produced FDA-authorized products and structured milestone and royalty pathways that reinforce external validation.

Product Line Growth: Multiple FDA authorizations (Rejoyn for MDD and CT-132 for migraine), the acquisition of AspyreRx, and an expanded pipeline spanning psychiatry, neurology, and cardiometabolic disease point to a broader, more mature portfolio. Positive Phase 3 results and commercialization preparations for CT-155 add momentum to this expansion.

Market Expansion: Public records and reporting indicate a major new regional headquarters and distribution center in Fort Worth, adding a sixth U.S. node to existing facilities in Illinois, Georgia, Ohio, California, and New Jersey. Additional buildouts at sites like Elmhurst and other regional renewals point to a broader, expanding nationwide footprint.

Innovation-Driven Growth: Project filings describe substantial automation investments at the Texas facility—high-bay racking, tote-shuttle systems, and conveyors—alongside hiring for reliability/automation roles. These moves signal scaling capacity with technology to support same- and next-day fulfillment.

Strong Market Position & Advantage: Industry coverage places the company near the top of MRO/industrial distributor rankings and highlights standout catalog breadth and rapid fulfillment. Company descriptions also cite serving hundreds of thousands of daily customers, indicating strong competitive presence.

Strong Market Position & Advantage: Market position is characterized as leading across key access categories, with products present in tens of millions of homes and a large myQ user base. This entrenched installed base and brand strength underpin ongoing commercial momentum.

Diversified Revenue Streams: Acquisitions such as Multi-Fab Products/Nova Technology explicitly added another revenue stream and extended the portfolio into loading-dock equipment and parts. This adjacency expansion reduces reliance on core garage access hardware alone.

Strong Revenue Growth: Credit-rating reports assume continued top-line increases in the near term, indicating a positive revenue trajectory. Company communications also frame the business as being on a growth path with expansion in smart/IoT services.

Market Expansion: International footprint is described as rapidly scaling, with the oncology research network tripling year over year and later noted as nearly 70% ex‑U.S. growth across the UK, Germany, Japan, and new regions like Scotland. Point‑of‑care reach is also portrayed as expanding, with 1,600+ sites of care and increases from earlier baselines.

Product Line Growth: New offerings include the launch of Flatiron Telescope and multiple AI-enabled datasets, alongside expansions of major assets such as the NSCLC Panoramic dataset. Additional capabilities like LLM-based data extraction and new hematology datasets indicate broader, monetizable product breadth.

Strategic Partnerships: Collaborations are highlighted with organizations such as NCCN, Quest Diagnostics, Candid Health, TailorMed, and DeepScribe, as well as a multi‑year partnership alongside the Paradigm transaction. Engagements with 20+ global oncology drug developers and academic institutions reinforce a partnership‑driven operating model.

Strong Revenue Growth: Revenue is rising at double-digit rates across recent periods, and management has increased full-year guidance, underscoring continued momentum. Growth is visible in both recent quarters and the prior year, indicating sustained top-line expansion.

Diversified Revenue Streams: Both Diagnostics and Data & Applications are expanding, with data-licensing/Insights activity increasing alongside clinical testing volumes. This mix reduces reliance on a single line of business and supports multiple growth vectors.

Strategic Partnerships: Collaborations with major biopharmaceutical companies and broader rollouts of platforms such as Next signal expanding commercial reach. Announced initiatives like a large whole‑genome dataset and work with firms including Merck reinforce external demand for the platform.

Market Expansion: Additions of sales-agent coverage across Texas/Arkansas/Oklahoma, the Northeast/NYC/NJ, and the Mountain West in 2026, plus growth to 18 North American locations with larger facilities (e.g., a 285,000+ sq.-ft. Atlanta site, a 200,000-sq.-ft. Tampa site, and a new Mississauga branch), point to broader reach. The completed Kingwire acquisition adds eight warehouses and more than 625,000 sq. ft., further densifying the network.

Product Line Growth: A dedicated Communications Business Unit and expanded industrial automation/communications portfolio, combined with Kingwire’s strengths in aluminum, utility, data centers, and renewables, indicate a broadened offering. Approximately $400M of stated inventory supports availability across the enlarged SKU set.

Investor Backing & Capital Strength: Completion of the 2026 Kingwire acquisition alongside maintaining roughly $400M of inventory and major facility investments suggests access to capital to fund scale. Backing from Dot Family Holdings and prior acquisitions reinforce the platform’s capital support.

Strong Revenue Growth: Recent results indicate total revenue increased year over year in 2025 and continued to rise in the latest reported quarter. Guidance and quarterly updates point to ongoing top-line expansion even as mix shifts occur.

Resilient & Sustainable Growth: Underlying annual contract value expanded and accelerated in 2026, with management indicating continued growth despite the transition to hosted licensing. This suggests the core subscription base is strengthening even when reported revenue timing varies.

Diversified Revenue Streams: Growth is visible in both the software business and the milestone-driven drug discovery segment. The latter stepped up meaningfully in recent periods, complementing steady software momentum.

Strong Revenue Growth: Annual revenue surpassed $1 billion and later exceeded $1.4 billion in 2025, with the parent company repeatedly identifying Zoro as a growth driver into 2026. Segment updates indicate continued momentum through late 2025 and mid‑2026.

Product Line Growth: The assortment expanded to roughly 13 million products, alongside scale indicators such as millions of annual web transactions and more than 4 million customers. This breadth reflects sustained investment in catalog depth to support sales.

Investor Backing & Capital Strength: As a wholly owned business within W.W. Grainger, Zoro benefits from the parent’s balance sheet, supply chain, and strategic emphasis on the Endless Assortment model. Company communications consistently highlight Zoro as a contributor to segment performance.

Product Line Growth: Growth across non‑COVID medicines such as Eliquis, Padcev, the Vyndaqel family, Lorbrena, Nurtec/Vydura and oncology biosimilars has been robust. Launched and acquired products are showing sustained double‑digit operational gains, adding meaningful momentum.

Resilient & Sustainable Growth: Excluding COVID products, the underlying portfolio delivered mid‑single‑digit operational growth in 2025 and continued at a similar pace in early 2026, more than offsetting part of the COVID‑related decline. Reported revenue also returned to modest year‑over‑year growth in the first half of 2026, indicating stabilization.

Future-Ready Strategy: Management raised the midpoint of 2026 revenue guidance and continues to invest heavily in a broad late‑stage pipeline. This posture signals confidence that newer launches and acquired assets can drive the next leg of growth.

Investor Backing & Capital Strength: Capital raising has accelerated, including a $372M Series D in 2024 with total funding reported in the hundreds of millions to expand the pipeline and AI platform. Valuation has stepped up from roughly $1.04B (2021) to about $1.48B post‑money (2024), signaling strengthened private‑market positioning.

Strategic Partnerships: Partnerships are expanding, highlighted by a collaboration with Sanofi and OpenAI to build AI software for drug development and increased business‑development capacity via Entrepreneurs in Residence. Engagements with large pharma partners, including Sanofi, underscore growing external validation and deal flow.

Product Line Growth: The pipeline is broadening through multiple in‑licenses—such as an anti‑CD226 program, a CNS‑penetrant TYK2 inhibitor, and a miR‑124 activator—and progression to first‑in‑human dosing of BLKR201 in 2026. Stated plans to reach 10–15 assets over 3–5 years align with recent portfolio expansion and clinical advancement.

Market Expansion: The platform’s footprint expanded from 400 participating sites in 2022 to 6,000+ sites by 2026, with presence across 50+ countries and 25+ sponsors. Evidence indicates marketplace adoption more than doubled in 2023 and activity surpassed 100 trials by 2024.

Product Line Growth: The offering broadened from a marketplace into AI-powered patient pre-screening and integrated workflows, with reported operational time savings and enrollment improvements in case studies. Subsequent integrations with CRIO, RealTime eClinical, and eClinPro signal continued platform expansion.

Strategic Partnerships: Relationships include major pharmaceutical organizations (e.g., 16 of the top 30 in 2024 and now 25+ sponsors) and ecosystem deals such as RealTime eClinical (50+ networks representing 2,000+ sites) plus CRIO/eClinPro integrations. These ties appear to extend distribution and enrich data used for site selection and enrollment.

Strong Market Position & Advantage: Adoption spans 1,300+ biotechnology organizations with usage reported across more than half of the top 50 biopharma companies, signaling durable positioning in life‑sciences R&D software. Multiple sources characterize the platform as a leading life‑sciences R&D cloud used by both startups and major enterprises.

Product Line Growth: The company continues to launch and expand major offerings, including Benchling AI, antibody‑discovery capabilities, automation/analysis tools, and extensions into new scientific workflows such as small‑molecule chemistry. Acquisitions like PipeBio further broaden capability depth in biologics and related R&D domains.

Innovation-Driven Growth: AI is a clear growth vector, with reports that 500 biotech companies used Benchling AI in its first year and the product subsequently reached general availability. Team acquisitions (e.g., ReSync Bio and Sphinx Bio) and partnerships (e.g., with Anthropic) underscore a deliberate push to embed advanced models into scientific workflows.

Strong Market Position & Advantage: CELLINK is widely characterized as a leader in 3D bioprinting, with broad adoption across thousands of academic and pharma labs and frequent inclusion among top players in industry overviews. Its end-to-end portfolio of extrusion and light-based bioprinters, bioinks, and software underpins this position.

Innovation-Driven Growth: Early category-defining moves (such as launching the first universal bioink) and continued expansion into advanced systems like BIO X/BIO X6, LUMEN X, and BIONOVA X highlight a sustained innovation engine. Acquisitions such as Allegro 3D broadened modalities and reinforced an integrated workflow approach.

Resilient & Sustainable Growth: Parent disclosures indicate a return to organic growth in early 2026 and note that turnarounds including CELLINK strengthened results after a choppy 2025. Segment commentary around Life Science Solutions (which includes CELLINK) points to stabilization despite soft academic end-markets.